Colloidal Bismuth Pectin Dispersion for Rapid Gastric Disintegration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional colloidal bismuth pectin preparations face challenges in achieving rapid disintegration and maintaining colloidal stability, which affects their ability to form a protective film in the stomach and meet clinical requirements for quick therapeutic effects and patient compliance.
Innovation Solution
A dispersion preparation containing colloidal bismuth pectin is developed using a combination of penetration enhancers, pore-forming agents, and disintegrating agents, ensuring rapid disintegration and dissolution within 3 minutes while maintaining colloidal stability, as per the Chinese Pharmacopoeia standards.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If colloidal stability is ensured during preparation, then the colloidal tablets can form protective film in the stomach, but the tablets are difficult to disintegrate quickly and meet dispersal uniformity requirements
Solution Approach 1:
The patent applies preliminary action by pre-coating the colloidal bismuth pectin particles with a hydrophobic coating material before tablet formation. This pre-coating prevents aggregation during storage and preparation while allowing rapid disintegration when exposed to gastric fluid, thus resolving the contradiction between colloidal stability and disintegration speed.
Solution Approach 2:
The patent utilizes parameter changes by controlling the pH environment and using effervescent agents that generate CO2 bubbles. The pH change and gas evolution during disintegration facilitate rapid breakdown of the tablet matrix while maintaining colloidal stability through controlled chemical transformations in the gastric environment.
2Productivity
If colloidal tablets are disintegrated quickly to meet dispersal uniformity, then dispersal requirements are met, but the stability of the colloidal is destroyed and protective film formation is compromised
Solution Approach 1:
The patent applies segmentation by dividing the tablet into numerous fine particles through controlled disintegration. The effervescent agents create bubbles that mechanically separate and disperse the colloidal particles uniformly throughout the gastric fluid, achieving both rapid disintegration and maintained colloidal stability through uniform distribution.
Solution Approach 2:
The patent uses effervescent agents as intermediaries that facilitate rapid disintegration through CO2 bubble generation. These bubbles act as a mediator that separates and disperses the colloidal particles without directly contacting or destabilizing the colloidal structure, enabling quick dispersal while preserving colloidal integrity.
3Ease of operation
If conventional capsule formulations are used, then the drug can be administered, but the release is slow and does not meet clinical requirements for quick therapeutic effects
Solution Approach 1:
The patent applies phase transitions by using effervescent agents that undergo rapid gas evolution upon contact with gastric fluid. This phase transition from solid to gas creates vigorous bubbling that rapidly disperses the tablet and accelerates drug release, providing quick therapeutic effects while maintaining ease of administration as a oral tablet.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables rapid therapeutic effects, improved patient compliance, and expanded market applications for colloidal bismuth pectin, while maintaining the mucosal protective properties and stability of the drug.
Implementation Method 1
the colloidal bismuth pectin is capable of forming gel to protect mucous membrane. Under endoscopic observation, the accumulation of colloidal bismuth pectin on surfaces of ulcers was greater than that of other membranes. Thus, it can be seen that the colloidal bismuth pectin has a good selection of adhesion
Implementation Method 2
wherein metallic bismuth is capable of killing Helicobacter pylori
Implementation Method 3
Dispersed tablet is capable of disintegrating rapidly in 3 minutes and dissolving out
Implementation Method 4
the colloidal bismuth pectin has excellent characteristics of colloid in acidic medium and is capable of forming gel to protect mucous membrane
Implementation Method 5
Dispersed tablet is capable of disintegrating rapidly in 3 minutes and dissolving out, and has characteristics of rapidly exerting therapeutic effects and high bioavailability
Data Source
AI summary
A dispersion preparation containing colloidal bismuth pectin is provided. 1g is adopted as a unit for the preparation. Each unit of the preparation includes: 44.0 to 900.0 mg of colloidal bismuth pectin, 1.0-500 mg of a penetration enhancer, 2.0-312.5mg of acid-source pore forming agent, 2.0-250.0mg of alkali-source pore forming agent and 1.0-400.0mg of a disintegrating agent.